Menu Search
Equities

Takeda Pharmaceutical Co Ltd

4502:TYO

Takeda Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)4,131.00
  • Today's Change10.00 / 0.24%
  • Shares traded1.27m
  • 1 Year change-1.29%
  • Beta0.9124
Data delayed at least 20 minutes, as of Nov 22 2024 04:42 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 15-Nov-24
Select bar for recommendation details.
Recommendations15-Nov-24
Buy2
Outperform6
Hold9
Sell0
Strong Sell0

Share price forecast in JPY

The 15 analysts offering 12 month price targets for Takeda Pharmaceutical Co Ltd have a median target of 4,750.00, with a high estimate of 5,900.00 and a low estimate of 4,200.00. The median estimate represents a 15.26% increase from the last price of 4,121.00.
High43.2%5,900.00
Med15.3%4,750.00
Low1.9%4,200.00

Dividends in JPY

In 2024, Takeda Pharmaceutical Co Ltd reported a dividend of 188.00 JPY, which represents a 4.44% increase over last year. The 14 analysts covering the company expect dividends of 196.00 JPY for the upcoming fiscal year, an increase of 4.26%.
Div growth (TTM)4.44%
More ▼

Earnings history & estimates in JPY

On Oct 31, 2024, Takeda Pharmaceutical Co Ltd reported 2nd quarter 2025 earnings of 58.14 per share. This result exceeded the 32.80 consensus of the 4 analysts covering the company and outperformed last year's 2nd quarter results by 89.14.
The next earnings announcement is expected on Jan 30, 2025.
Average growth rate-4.23%
Takeda Pharmaceutical Co Ltd reported annual 2024 earnings of 92.09 per share on May 09, 2024.
Average growth rate+173.09%
More ▼

Revenue history & estimates in JPY

Takeda Pharmaceutical Company Limited had 2nd quarter 2025 revenues of 1.18bn. This bettered the 1.09bn consensus of the 7 analysts covering the company. This was 11.09% above the prior year's 2nd quarter results.
Average growth rate+3.35%
Takeda Pharmaceutical Company Limited had revenues for the full year 2024 of 4.26bn. This was 5.87% above the prior year's results.
Average growth rate+6.87%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.